Assessment of the Feasibility of Using a Smartphone Application for the Prevention and Screening of Burnout (BURNOUT ADVICE)

Sponsor
Weprom (Other)
Overall Status
Recruiting
CT.gov ID
NCT05011435
Collaborator
Kelindi (Industry)
200
1
11.5
17.3

Study Details

Study Description

Brief Summary

Burnout syndrome has been recognized as a mental illness since 2020. All workers can be affected. The consequences are multiple and often serious, ranging from stoppage of work to depression or even suicide. According to a 2019 survey by Malakoff, 56% of employees are in "professional or personal fragility", but the statistics are incomplete.

In the medical community, the burnout rate is doubled compared to the general population.

The diagnosis of pre-burnout can precede a burnout by several months, an early treatment can then reduce complications and improve the quality of life at work.

On a study model on health data already carried out as part of a cancer detection application in smokers which involved 7000 users and which showed the ability to of such an application to detect curable symptomatic cancers from questionnaires (24% with application against 9% without application), we will carry out a descriptive evaluation of the use of an application to detect pre-burnout, burnout and depressive syndrome in a worker population. In the event of a risk alert of pre-burnout, burnout or depressive syndrome, the application will display a message to the user suggesting that he consult his general practitioner or put him in contact with a doctor through a teleconsultation via a dedicated platform.

This first study will assess the feasibility and acceptability of an early detection approach among professionals of a state of "fragility" (pre-burnout, burnout or depressive syndrome). Subsequently, a larger study will evaluate the effectiveness of this application for the early detection of burnout among professionals, its management and the reduction of costs for the healthcare system and society.

Condition or Disease Intervention/Treatment Phase
  • Device: web-application for burnout

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Assessment of the Feasibility of Using a Smartphone Application for the Prevention and Screening of Burnout
Actual Study Start Date :
Sep 15, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Users

users of the web-application

Device: web-application for burnout
Use of burnout advisor web-application for detection of professional burnout
Other Names:
  • Burnout Advisor
  • Outcome Measures

    Primary Outcome Measures

    1. usefulness [6 months]

      number of users who find the application useful

    Secondary Outcome Measures

    1. alert [6 months]

      Description of alerts triggered by algorithms

    2. Consultation [6 months]

      Number of relevant consultations (or teleconsultations) after an alert

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 64 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Person aged 18 to 64

    • Exercising a professional activity

    • User informed of the use of this data and not objecting to it

    Exclusion Criteria:
    • Professionals on sick leave

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 ILC Le Mans France 72000

    Sponsors and Collaborators

    • Weprom
    • Kelindi

    Investigators

    • Study Director: Fabrice DENIS, Pr, ILC

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weprom
    ClinicalTrials.gov Identifier:
    NCT05011435
    Other Study ID Numbers:
    • WP-2021-01
    First Posted:
    Aug 18, 2021
    Last Update Posted:
    Nov 3, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 3, 2021